The First Trust Water ETF (FIW) is a passively managed fund with $1.71 billion in assets that tracks the ISE Clean Edge Water Index. It has a 0.5% expense ratio and 0.76% dividend yield. The fund has declined 3.23% year-to-date and 7.75% over the past year, with a beta of 0.99 indicating medium risk. It carries a Zacks ETF Rank of 3 (Hold) and is compared to alternative water ETFs like CGW and PHO.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

Medtronic reported strong Q1 fiscal 2027 results with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7% YoY), both beating consensus estimates. The company raised full-year organic revenue growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. However, shares have declined 6.4% since the earnings report, underperforming the S&P 500. Analyst estimates have trended downward post-earnings, and the stock carries a Zacks Rank #3 (Hold) rating.

A $1,000 investment in Agilent Technologies made in September 2016 would be worth $3,583.89 as of September 23, 2026, representing a 258.39% gain. This outperforms the S&P 500's 256.64% return over the same period. Analysts expect continued upside driven by instrument replacement demand, pharma exposure, and expanding specialty CDMO activity, though headwinds remain in academia, government, Europe, and China.

The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.

The global magnetic bead purification kits market reached $4.08 billion in 2025 with an 11.6% CAGR and is projected to grow to $6.73 billion by 2030 (10.5% CAGR) and $10.42 billion by 2035 (9.1% CAGR). Growth is driven by expanding genomics research, molecular diagnostics, and high-throughput screening. Semi-automated kits dominate at 51.8% market share, while Asia-Pacific is the fastest-growing region at 12% CAGR. Key challenges include skilled labor shortages and automation infrastructure dependencies.

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

Agilent Technologies reported Q3 2026 total revenue of $1.88 billion, up 8.1% year-over-year. Europe contributed $504 million (26.8%), missing analyst expectations by 3.24%, while Asia Pacific delivered $613 million (32.6%), beating estimates by 3.15%. The company holds a Zacks Rank #3 (Hold) rating, with stock gaining 11.2% over the past month versus the S&P 500's 3.9% increase.

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

The global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.